| REVIEW ARTICLE |
|
| Year : 2014 | Volume
: 1
| Issue : 1 | Page : 7-15 |
|
|
In Vitro Maturation
Jayant G Mehta
Director Sub-Fertility Laboratory and Quality Control Manager, Barking Havering and Redbridge University Hospitals, National Health Service Trust, Queen's Hospital, Rom Valley Way, Romford, RM7 0AG, Essex, London, United Kingdom
Correspondence Address:
Dr. Jayant G Mehta
Director Sub-Fertility Laboratory and Quality Control Manager, Barking Havering and Redbridge University Hospitals, National Health Service Trust, Queen's Hospital, Rom Valley Way, Romford, RM7 0AG, Essex, London
United Kingdom
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2394-4285.146700
|
|
|
In vitro maturation (IVM) of the human oocytes has recently found an important niche among assisted reproductive techniques (ART). Even though the ovarian stimulation protocols continue to evolve and last for few days, they are still not patient-friendly. The development of several follicles is associated with a high risk of ovarian hyperstimulation syndrome (OHSS), leading to hospitalization that can be fatal. Natural IVF cycles, mild stimulation with low dose gonadotrophins and IVM of human oocytes ready for fertilisation now offer an alternative to the traditional IVF treatment. Infertile women with polycystic ovaries or polycystic ovarian syndrome (PCOS) form the main category of patients who would benefit from IVM. However, concern exists that IVM may interfere at the epigenetic level and in particular with genomic imprinting. For normal embryonic development, timely acquisition of correct imprinting patterns in oocytes and maintenance of genomic imprinting after fertilisation is required. It is therefore necessary that patients undergoing IVM be offered preimplantation genetics screening (PGS) prior to embryo transfers. This review considers our current understanding of in-vitro maturation of human oocytes and its importance in clinical applications. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
